The failure of hormonal and cytotoxic chemotherapy in the treatment of recurrent meningioma and increasing understanding of potential molecular targets in meningioma has resulted in multiple studies utilizing single-agent targeted therapy directed at biologically relevant signaling pathways, such as [[somatostatin]] (Sandostatin(®) LAR, SOM230c), PDGF ([[imatinib]]), EGF ([[erlotinib]]) and VEGF (sunitinib and [[vatalanib]])
((Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent
meningiomas. Expert Rev Neurother. 2011 Oct;11(10):1425-32. doi:
10.1586/ern.11.38. Review. PubMed PMID: 21955199.
)).